Drug intelligence / Profile preview

ICE-TUBE

Development stage: Preclinical
Lead developer: GN Corporation
Modality: Hydrogel Systems → Drug Delivery Systems, Cell Therapies
Administration: Ophthalmic

Overview

ICE-TUBE is an investigational donor-derived corneal endothelial cell therapy developed by GN Corporation and the Nichi-In Centre for Regenerative Medicine for corneal endothelial disease, including bullous keratopathy. The approach expands corneal endothelial precursor cells isolated from a single cadaver donor cornea and transplants them into recipient eyes using BLIS-FILM, a nanocomposite gel-film scaffold intended to support cell attachment and engraftment. The program is intended to restore corneal endothelial function and reduce dependence on full donor-corneal transplantation. ([gncorporation.com](https://gncorporation.com/en/consulting-research-patents-en/cell-therapy-solutions-en/))

Other names: Eye-for-Eyes Mission

Beyond the preview

Go deeper on ICE-TUBE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICE-TUBE.

Explore the full profile